Asset Details
Do you wish to reserve the book?
Novel Sigma-1 receptor agonist alleviates renal ischemic injury by targeting apoptotic and inflammatory pathways
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Novel Sigma-1 receptor agonist alleviates renal ischemic injury by targeting apoptotic and inflammatory pathways
Do you wish to request the book?
Novel Sigma-1 receptor agonist alleviates renal ischemic injury by targeting apoptotic and inflammatory pathways
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Novel Sigma-1 receptor agonist alleviates renal ischemic injury by targeting apoptotic and inflammatory pathways
2025
Overview
Renal ischemia-reperfusion injury (IRI) is a major cause of acute kidney injury, yet its mechanisms remain unclear, and effective treatments are lacking. We previously showed that the Sigma-1 receptor (S1R) agonist fluvoxamine protects against IRI and IRI-induced graft injury during transplantation. Here, we developed a novel compound, ‘VCC904125’, with potent S1R affinity and minimal blood-brain barrier penetration to mitigate renal IRI without psychoactive side effects. Mice were treated with VCC904125 before clamping the left renal pedicles, followed by contralateral nephrectomy. VCC904125 markedly alleviated BUN and serum creatinine levels, KIM-1 and NGAL expression, and structural damage at both 24 and 48 h after reperfusion. S1R activation by VCC904125 targets key pathways underlying IRI, including apoptosis and inflammation. VCC904125 treatment impeded the apoptotic p53-Bax pathway and influenced CaMKII-NF-κB signaling, resulting in diminished proinflammatory cytokine expression. In the ex vivo model, kidneys were perfused and stored in an HTK preservation solution supplemented with VCC904125 to simulate cold storage conditions before transplantation. VCC904125 ameliorated structural injury profoundly after cold ischemia. Taken together, S1R activation by VCC904125 decreases renal IRI via ameliorating apoptotic and inflammatory pathways. These results highlight the therapeutic promise of S1R activation in mitigating cold and warm ischemia and improving transplant outcomes.
Publisher
Nature Publishing Group UK,Nature Publishing Group,Nature Portfolio
Subject
/ Acute Kidney Injury - drug therapy
/ Acute Kidney Injury - metabolism
/ Acute Kidney Injury - pathology
/ Agonists
/ Animals
/ Ca2+/calmodulin-dependent protein kinase II
/ Hepatitis A Virus Cellular Receptor 1 - metabolism
/ Humanities and Social Sciences
/ Ischemia
/ Kidneys
/ Ligands
/ Male
/ Mice
/ Proteins
/ Receptors, sigma - metabolism
/ Renal ischemia/reperfusion injury
/ Reperfusion Injury - drug therapy
/ Reperfusion Injury - metabolism
/ Reperfusion Injury - pathology
/ Science
